Enliven (NASDAQ: ELVN) director sells 10,000 shares via 10b5-1 plan

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Enliven Therapeutics director Lori Anne Kunkel reported open-market sales of 10,000 shares of Enliven Therapeutics, Inc. common stock on June 5, 2026, executed in multiple trades under a Rule 10b5-1 trading plan adopted on March 6, 2026.

The shares were sold in three transactions at weighted average prices of $34.2794, $35.3573, and $35.8187 per share. After these sales, she held 51,884 shares of common stock directly.

Insider Trade Summary 10b5-1

Net Seller: 10,000 shares ($345,351)

Net Sell 4 txns

Insider Kunkel Lori Anne

Role null

Sold 10,000 shs ($345K)

Type	Security	Shares	Price	Value
Sale	Common Stock	7,779	$34.2794	$267K
Sale	Common Stock	1,867	$35.3573	$66K
Sale	Common Stock	354	$35.8187	$13K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 54,105 shares (Direct, null); Common Stock — 0 shares (Indirect, See footnote)

Footnotes (1)

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2026 This transaction was executed in multiple trades at prices ranging from $33.7383 to $34.7358. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. The number of shares held reflects the transfer of 31,172 shares of Common Stock from Lori Kunkel Revocable Trust DTD 11/08/2018 Lori A Kunkel TTEE to the Reporting Person . This transaction was executed in multiple trades at prices ranging from $34.759 to $35.7574. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. This transaction was executed in multiple trades at prices ranging from $35.7595 to $35.9456. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. The shares were held by Lori Kunkel Revocable Trust DTD 11/08/2018 Lori A Kunkel TTEE.

Key Figures

Shares sold: 10,000 shares Weighted average sale price 1: $34.2794 per share Weighted average sale price 2: $35.3573 per share +4 more

7 metrics

Shares sold 10,000 shares Aggregate common stock sold on June 5, 2026

Weighted average sale price 1 $34.2794 per share One of three reported sale transactions

Weighted average sale price 2 $35.3573 per share One of three reported sale transactions

Weighted average sale price 3 $35.8187 per share One of three reported sale transactions

Shares held after transactions 51,884 shares Direct common stock ownership following June 5, 2026 sales

Trading plan adoption date March 6, 2026 Rule 10b5-1 plan covering the reported sales

Net buy/sell direction Net-sell of 10,000 shares Form 4 transaction summary for June 5, 2026

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, revocable trust, open-market sale

4 terms

Rule 10b5-1 trading plan regulatory

"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"The price reported above reflects the weighted average sale price."

revocable trust financial

"The shares were held by Lori Kunkel Revocable Trust DTD 11/08/2018 Lori A Kunkel TTEE."

A revocable trust is a legal arrangement where the person who creates it keeps control and can change or cancel the trust at any time, while naming who will manage and receive the assets later. Think of it like a flexible folder for your investments and property that can be relabeled or reworked as circumstances change; it matters to investors because it determines how ownership is recorded, how easily assets transfer on incapacity or death, and whether holdings bypass public probate proceedings.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/09/2026 - 04:49 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kunkel Lori Anne

(Last)

(First)

(Middle)

C/O ENLIVEN THERAPEUTICS, INC.

205 PARK ROAD

(Street)

BURLINGAME

CALIFORNIA

94010

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Enliven Therapeutics, Inc. [ ELVN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/05/2026		S⁽¹⁾		7,779	D	$34.2794⁽²⁾	54,105⁽³⁾	D
Common Stock	06/05/2026		S⁽¹⁾		1,867	D	$35.3573⁽⁴⁾	52,238	D
Common Stock	06/05/2026		S⁽¹⁾		354	D	$35.8187⁽⁵⁾	51,884	D
Common Stock								0⁽³⁾	I	See footnote⁽⁶⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2026

2. This transaction was executed in multiple trades at prices ranging from $33.7383 to $34.7358. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

3. The number of shares held reflects the transfer of 31,172 shares of Common Stock from Lori Kunkel Revocable Trust DTD 11/08/2018 Lori A Kunkel TTEE to the Reporting Person .

4. This transaction was executed in multiple trades at prices ranging from $34.759 to $35.7574. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

5. This transaction was executed in multiple trades at prices ranging from $35.7595 to $35.9456. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

6. The shares were held by Lori Kunkel Revocable Trust DTD 11/08/2018 Lori A Kunkel TTEE.

	/s/ Ben Hohl, by power of attorney	06/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Enliven Therapeutics (ELVN) disclose for Lori Anne Kunkel?

Enliven Therapeutics disclosed that director Lori Anne Kunkel sold 10,000 shares of common stock on June 5, 2026. The Form 4 shows these were open-market sales executed in multiple trades under a pre-established Rule 10b5-1 trading plan.

At what prices did Lori Anne Kunkel sell Enliven Therapeutics (ELVN) shares?

Lori Anne Kunkel sold Enliven Therapeutics common stock at weighted average prices of $34.2794, $35.3573, and $35.8187 per share. Footnotes note that each transaction involved multiple trades within specified price ranges around those averages.

How many Enliven Therapeutics (ELVN) shares does Lori Anne Kunkel hold after this Form 4?

Following the reported June 5, 2026 sales, Lori Anne Kunkel directly holds 51,884 shares of Enliven Therapeutics common stock. The filing also reflects prior transfers from the Lori Kunkel Revocable Trust into her direct ownership position.

Was the Enliven Therapeutics (ELVN) insider sale made under a Rule 10b5-1 plan?

Yes. A footnote states the sales were effected under a Rule 10b5-1 trading plan adopted by Lori Anne Kunkel on March 6, 2026. Such plans pre-schedule trades, which can make the timing less indicative of near-term company outlook.

How many Enliven Therapeutics (ELVN) shares did Lori Anne Kunkel sell in total?

Across three open-market sale transactions on June 5, 2026, Lori Anne Kunkel sold a total of 10,000 Enliven Therapeutics common shares. The Form 4 transaction summary reports aggregate sellShares of 10,000 and a net-sell direction.

What role does the revocable trust play in Enliven Therapeutics (ELVN) holdings?

The filing notes that shares were held by the Lori Kunkel Revocable Trust and that 31,172 shares were transferred from the trust to Lori Kunkel. This clarifies movement from indirect trust ownership to her direct ownership of Enliven Therapeutics shares.